First Patient Advanced Prostate Cancer Treated with Harpoon Therapeutics’ HPN424

First Patient Advanced Prostate Cancer Treated with Harpoon Therapeutics’ HPN424
A Phase 1 clinical trial of Harpoon Therapeutics’ immunotherapy candidate, HPN424 for metastatic castration-resistant prostate cancer (mCRPC), has treated the first patient, according to the company. HPN424 uses the Harpoon’s TriTAC (Tri-specific T cell Activating Construct) platform. This approach is intended to work as an adaptor, connecting the patient’s own immune T-cells with tumor cells. This is possible because TriTAC products target cancer cells and immune cells at the same time, bringing them together. HPN424, particularly, is a bi-specific antibody (aka T-cell engager) that binds the PSMA protein — found in more than 90 percent of mCRPC lesions — and the CD3 molecule on T-cells. Harpoon designed HPN-424 to be the smallest T-cell engager to penetrate solid tumors with superior effectiveness, last longer in the blood, and recruit patients’ T-cells to kill malignant cancer cells. The multicenter, international, open-label study (NCT03577028) will assess the safety, tolerability and pharmacokinetics (the study of a compound’s absorption, distribution, metabolism, and excretion) of HPN424 in approximately 40 adult patients with mCRPC. Patient recruitment is underway at the Sarah Cannon Research Institute, in Nashville, Tennessee. (More information and contacts
Subscribe or to access all post and page content.